Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
about
Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.New drug therapies in peripheral T-cell lymphoma.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma.Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.Phase II study of low-dose fixed-rate infusion of gemcitabine combined with cisplatin and dexamethasone in resistant non-Hodgkin lymphoma and correlation with Bcl-2 and MDR expression.CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
P2860
Q24813078-C90FE1C7-3FF2-4250-9911-0D7BE9AE58C3Q33365711-095EFD4E-3799-4034-907A-7D448D72E752Q33402306-D301C727-91DD-46A5-B884-5C86DFEA81CBQ33409608-5F38FF34-2F4B-4485-89F1-77B5B2DDF446Q33411127-81C37221-0BD4-4819-A322-3247900E362DQ33425005-D6C9BC84-0BE4-4017-92B5-DB502D120768Q37854715-351E11C2-723C-4A44-9E05-F1B70CB553BDQ37863688-0EDD3A15-8B2F-41CB-BBB5-F99D6C72D1F8Q38028856-5925375C-91FA-4BCD-9884-15FC6191C394Q38738390-1316DA46-EC14-4DD0-9BAB-B8C6ED819F58Q43249154-74715E4D-2240-4EE7-845E-D959B690A81AQ43814680-FAA19874-F37F-4E6F-90A5-A842D1B07336Q46061398-27851A30-91B3-485C-A271-AF1202E4F76EQ48301800-B9B425B9-60CD-492A-987A-039114AD6359Q53095626-F74F87B6-3196-45F9-9E21-B52DFFC44D96Q53828417-C454B44C-5F5D-40DF-9E26-53EB66DD90F0
P2860
Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Pilot study of fixed-infusion ...... lapsed or refractory lymphoma.
@ast
Pilot study of fixed-infusion ...... lapsed or refractory lymphoma.
@en
type
label
Pilot study of fixed-infusion ...... lapsed or refractory lymphoma.
@ast
Pilot study of fixed-infusion ...... lapsed or refractory lymphoma.
@en
prefLabel
Pilot study of fixed-infusion ...... lapsed or refractory lymphoma.
@ast
Pilot study of fixed-infusion ...... lapsed or refractory lymphoma.
@en
P2093
P356
P1476
Pilot study of fixed-infusion ...... lapsed or refractory lymphoma.
@en
P2093
Christos Colovos
Christos Emmanouilides
Gary Schiller
Lauren Pinter-Brown
Luis Hernandez
Mary Territo
Peter Rosen
P356
10.3816/CLM.2004.N.009
P577
2004-06-01T00:00:00Z